Clinical Trial

Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of MK-3475 in patients with ovarian squamous cell carcinoma.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-02-12; most recent amendment 2026-02-03.
Status change: Recruiting → Active, Not Recruiting 2026-02-03
Status change: Not Yet Recruiting → Recruiting 2023-05-08
Trial Details
NCT Number NCT05737199
Lead Sponsor Niigata University Medical & Dental Hospital
Collaborators: Merck Sharp & Dohme LLC
Conditions Ovarian Squamous Cell Carcinoma
Enrollment 21 participants
Start Date 2023-05-01
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-05